Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRX-15
- Development stage
- Preclinical
- Lead developer
- MicuRx
- Modality
- Small Molecules
01
Overview
MRX-15 is a preclinical-stage small molecule drug candidate being developed by MicuRx Pharmaceuticals for the treatment of kidney cancer, specifically renal cell carcinoma. The compound is part of MicuRx's kidney disease pipeline and utilizes the company's proprietary renal-targeted delivery platform technology. This platform is designed to increase local drug concentration within the kidney while simultaneously reducing systemic exposure and associated toxicity. By enabling the targeted distribution of chemically modified drug entities to renal tissues, MRX-15 aims to provide a safer and more effective therapeutic option for patients with renal malignancies compared to conventional systemic therapies.
Beyond the preview
Go deeper on MRX-15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRX-15.